Infusyn Therapeutics
Source from Infusyn Therapeutics
Send an enquiry directly.
About Infusyn Therapeutics
Infusyn Therapeutics manufactures the Prometra II, an implantable, fully programmable drug delivery system designed for precise, targeted therapeutic administration. The Prometra II features Infusyn's proprietary Precision Dosing System (PDS), engineered to deliver medication with exceptional accuracy while minimizing variability from reservoir volume,…
Read full company overview
Infusyn Therapeutics manufactures the Prometra II, an implantable, fully programmable drug delivery system designed for precise, targeted therapeutic administration. The Prometra II features Infusyn's proprietary Precision Dosing System (PDS), engineered to deliver medication with exceptional accuracy while minimizing variability from reservoir volume, temperature, and pressure fluctuations. Currently FDA-approved for pain and spasticity management, the system enables physicians to achieve individualized, flexible dosing regimens with unrivaled consistency. Infusyn is expanding Prometra applications across multiple therapeutic indications through strategic partnerships, including development for pulmonary arterial hypertension (PAH). The company serves hospital systems, specialty clinics, and pain management centers requiring implantable infusion solutions with superior dosing reliability and patient-centric programmability.
Company information is compiled from public sources and may be out of date. It is not an endorsement or medical advice.
Products
- —
Prometra II Implantable Programmable Pump
Fully implantable drug delivery system with Precision Dosing System (PDS) for accurate, reliable medication administration. Approved for pain and spasticity treatment with flexible, physician-programmable dosing.
Request quote - —
Precision Dosing System (PDS)
Proprietary dosing technology that minimizes the effects of reservoir volume, temperature, and environmental pressure on drug delivery accuracy and consistency.
Request quote - —
PulmoProst (Development Stage)
Investigational drug candidate for pulmonary arterial hypertension (PAH) in development with strategic partners, leveraging Prometra delivery platform.
Request quote
Send an Enquiry
Or contact directly
Need a structured price?
Submit an RFP to compare Infusyn Therapeutics alongside up to 4 other vendors. Sealed responses, side-by-side at the deadline.
Submit an RFP